Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects

European Journal of Nutrition

Volumn 57, Issue 3, 2018, Pages 929-938

  Purpura, Martin ^a   Lowery, Ryan P ^b   Wilson, Jacob M ^b   Mannan, Haider ^e   Münch, Gerald ^c,e   Razmovski Naumovski, Valentina ^c,d  

^a Increnovo LLC ^*  (United States)

^b UNIVERSITY OF TAMPA   (United States)

^c WESTERN SYDNEY UNIVERSITY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Bioavailability; Curcumin; Cyclodextrin; Humans; Plasma pharmacokinetics

Indexed keywords

CURCUMIN; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; ESSENTIAL OIL; TURMERIC; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BIS(4-HYDROXYCINNAMOYL)METHANE; FOOD ADDITIVE; GAMMA CYCLODEXTRIN DERIVATIVE; GAMMA-CYCLODEXTRIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIETARY SUPPLEMENT; FOOD HANDLING; INTESTINE ABSORPTION; METABOLISM; NUTRITIONAL VALUE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; AREA UNDER CURVE; COHORT STUDIES; CROSS-OVER STUDIES; CURCUMIN; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOOD ADDITIVES; FOOD HANDLING; GAMMA-CYCLODEXTRINS; HUMANS; INTESTINAL ABSORPTION; MALE; NUTRITIVE VALUE; YOUNG ADULT;

EID: 85012894814     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-016-1376-9     Document Type: Article

References (38)

1. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV (2008) Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci CMLS 65(11):1631–1652. doi:10.1007/s00018-008-7452-4
2. Venigalla M, Gyengesi E, Münch G (2015) Curcumin and Apigenin—novel and promising therapeutics against chronic neuroinflammation in Alzheimer’s disease. Neural Regen Res 10(8):1181–1185. doi:10.4103/1673-5374.162686
3. Venigalla M, Sonego S, Gyengesi E, Sharman MJ, Münch G (2015) Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer’s disease. Neurochem Int. doi:10.1016/j.neuint.2015.10.011
4. Bharti AC, Donato N, Aggarwal BB (2003) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171(7):3863–3871
5. Karunaweera N, Raju R, Gyengesi E, Münch G (2015) Plant polyphenols as inhibitors of NF-kappaB induced cytokine production-a potential anti-inflammatory treatment for Alzheimer’s disease? Front Mol Neurosci 8:24. doi:10.3389/fnmol.2015.00024
6. Millington C, Sonego S, Karunaweera N, Rangel A, Aldrich-Wright JR, Campbell IL, Gyengesi E, Münch G (2014) Chronic neuroinflammation in Alzheimer’s disease: new perspectives on animal models and promising candidate drugs. Biomed Res Int 2014:309129. doi:10.1155/2014/309129
7. Hansen E, Krautwald M, Maczurek AE, Stuchbury G, Fromm P, Steele M, Schulz O, Garcia OB, Castillo J, Korner H, Münch G (2010) A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds. J Alzheimer’s Dis 19(2):451–464. doi:10.3233/JAD-2010-1233
8. Menon VP, Sudheer AR (2007) Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595:105–125. doi:10.1007/978-0-387-46401-5_3
9. Lev-Ari S, Maimon Y, Strier L, Kazanov D, Arber N (2006) Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J Soc Integr Oncol 4(1):21–26
10. Abe Y, Hashimoto S, Horie T (1999) Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res Off J Italian Pharmacol Soc 39(1):41–47. doi:10.1006/phrs.1998.0404
11. Asher GN, Spelman K (2013) Clinical utility of curcumin extract. Altern Ther Health Med 19(2):20–22
12. Bhattacharyya S, Mandal D, Saha B, Sen GS, Das T, Sa G (2007) Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 282(22):15954–15964. doi:10.1074/jbc.M608189200
13. Chandran B, Goel A (2012) A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res PTR 26(11):1719–1725. doi:10.1002/ptr.4639
14. Jagetia GC, Aggarwal BB (2007) “Spicing up” of the immune system by curcumin. J Clin Immunol 27(1):19–35. doi:10.1007/s10875-006-9066-7
15. DiSilvestro RA, Joseph E, Zhao S, Bomser J (2012) Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 11:79. doi:10.1186/1475-2891-11-79
16. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4(6):807–818. doi:10.1021/mp700113r
17. Wahlstrom B, Blennow G (1978) A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 43(2):86–92
18. Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J (2014) The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res 58(3):516–527. doi:10.1002/mnfr.201300724
19. Ammon HP, Wahl MA (1991) Pharmacology of Curcuma longa. Planta Med 57(1):1–7. doi:10.1055/s-2006-960004
20. Holder GM, Plummer JL, Ryan AJ (1978) The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 8(12):761–768
21. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, Gescher A (2001) Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61(3):1058–1064
22. Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, Kobayashi M (2011) Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci USA 108(16):6615–6620. doi:10.1073/pnas.1016217108
23. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE (2008) Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17(6):1411–1417. doi:10.1158/1055-9965.EPI-07-2693
24. Tan S, Calani L, Bresciani L, Dall’asta M, Faccini A, Augustin MA, Gras SL, Del Rio D (2015) The degradation of curcuminoids in a human faecal fermentation model. Int J Food Sci Nutr 66(7):790–796. doi:10.3109/09637486.2015.1095865
25. Szejtli J (1994) Medicinal applications of cyclodextrins. Med Res Rev 14(3):353–386
26. Pinho E, Grootveld M, Soares G, Henriques M (2014) Cyclodextrins as encapsulation agents for plant bioactive compounds. Carbohydr Polym 101:121–135. doi:10.1016/j.carbpol.2013.08.078
27. Ikeda S, Uchida T, Ichikawa T, Watanabe T, Uekaji Y, Nakata D, Terao K, Yano T (2010) Complexation of tocotrienol with gamma-cyclodextrin enhances intestinal absorption of tocotrienol in rats. Biosci Biotechnol Biochem 74(7):1452–1457. doi:10.1271/bbb.100137
28. Terao K, Nakata D, Fukumi H, Schmid G, Arima H, Hirayama F, Uekama K (2006) Enhancement of oral bioavailability of coenzyme Q10 by complexation with gamma-cyclodextrin in healthy adults. Nutr Res 26:503–508
29. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM (2011) Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74(4):664–669. doi:10.1021/np1007262
30. Wakabayashi M, Fishman WH (1961) A method for freeing Helix pomatia beta-glucuronidase of sulfatase by simple heat denaturation. Biochim Biophys Acta 48:195–197
31. Jager R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM (2014) Comparative absorption of curcumin formulations. Nutr J 13:11. doi:10.1186/1475-2891-13-11
32. Liu A, Lou H, Zhao L, Fan P (2006) Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal 40(3):720–727. doi:10.1016/j.jpba.2005.09.032
33. Zhang Y, Huo M, Zhou J, Xie S (2010) PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 99(3):306–314. doi:10.1016/j.cmpb.2010.01.007
34. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S (2008) A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 70(4):445–449. doi:10.4103/0250-474X.44591
35. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T (2011) Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34(5):660–665
36. Yallapu MM, Nagesh PK, Jaggi M, Chauhan SC (2015) Therapeutic applications of curcumin nanoformulations. AAPS J 17(6):1341–1356. doi:10.1208/s12248-015-9811-z
37. Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6:10. doi:10.1186/1472-6882-6-10
38. Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K, Soni MG (2011) Safety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studies. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc 49(8):1834–1842. doi:10.1016/j.fct.2011.05.001